Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 1430

1.

The safety profile of varicella vaccine: a 10-year review.

Galea SA, Sweet A, Beninger P, Steinberg SP, Larussa PS, Gershon AA, Sharrar RG.

J Infect Dis. 2008 Mar 1;197 Suppl 2:S165-9. doi: 10.1086/522125. Review.

PMID:
18419392
2.

The postmarketing safety profile of varicella vaccine.

Sharrar RG, LaRussa P, Galea SA, Steinberg SP, Sweet AR, Keatley RM, Wells ME, Stephenson WP, Gershon AA.

Vaccine. 2000 Nov 22;19(7-8):916-23.

PMID:
11115716
3.

Safety profile of live varicella virus vaccine (Oka/Merck): five-year results of the European Varicella Zoster Virus Identification Program (EU VZVIP).

Goulleret N, Mauvisseau E, Essevaz-Roulet M, Quinlivan M, Breuer J.

Vaccine. 2010 Aug 16;28(36):5878-82. doi: 10.1016/j.vaccine.2010.06.056. Epub 2010 Jun 30.

PMID:
20600487
4.

Molecular characterisation of varicella-zoster virus strains in Germany and differentiation from the Oka vaccine strain.

Sauerbrei A, Eichhorn U, Gawellek S, Egerer R, Schacke M, Wutzler P.

J Med Virol. 2003 Oct;71(2):313-9.

PMID:
12938208
5.

Viral strain identification in varicella vaccinees with disseminated rashes.

LaRussa P, Steinberg SP, Shapiro E, Vazquez M, Gershon AA.

Pediatr Infect Dis J. 2000 Nov;19(11):1037-9. Erratum in: Pediatr Infect Dis J 2001 Jan;20(1):33.

PMID:
11099082
6.

Differentiation of oka varicella vaccine strain from wild varicella-zoster virus strains isolated from vaccinees and household contact.

Shiraki K, Horiuchi K, Asano Y, Yamanishi K, Takahashi M.

J Med Virol. 1991 Feb;33(2):128-32.

PMID:
1675658
7.

Polymerase chain reaction and restriction fragment length polymorphism analysis of varicella-zoster virus isolates from the United States and other parts of the world.

LaRussa P, Steinberg S, Arvin A, Dwyer D, Burgess M, Menegus M, Rekrut K, Yamanishi K, Gershon A.

J Infect Dis. 1998 Nov;178 Suppl 1:S64-6.

PMID:
9852977
8.
9.

Vaccine-strain varicella zoster virus causing recurrent herpes zoster in an immunocompetent 2-year-old.

Ota K, Kim V, Lavi S, Ford-Jones EL, Tipples G, Scolnik D, Tellier R.

Pediatr Infect Dis J. 2008 Sep;27(9):847-8. doi: 10.1097/INF.0b013e318170af75.

PMID:
18664930
11.
12.
14.

Molecular characterization of clinical varicella-zoster strains from India and differentiation from the oka vaccine strain.

Kaushik KS, Lahiri KK, Chumber SK, Gupta RM, Kumar S, Kapila K, Karade S.

Jpn J Infect Dis. 2008 Jan;61(1):65-7.

15.

An evaluation of single nucleotide polymorphisms used to differentiate vaccine and wild type strains of varicella-zoster virus.

Quinlivan M, Gershon AA, Steinberg SP, Breuer J.

J Med Virol. 2005 Jan;75(1):174-80.

PMID:
15543576
17.

Ten year follow-up of healthy children who received one or two injections of varicella vaccine.

Kuter B, Matthews H, Shinefield H, Black S, Dennehy P, Watson B, Reisinger K, Kim LL, Lupinacci L, Hartzel J, Chan I; Study Group for Varivax..

Pediatr Infect Dis J. 2004 Feb;23(2):132-7.

PMID:
14872179
18.

Immunogenicity of Oka/Merck varicella vaccine in children vaccinated at 12-14 months of age versus 15-23 months of age.

Silber JL, Chan IS, Wang WW, Matthews H, Kuter BJ.

Pediatr Infect Dis J. 2007 Jul;26(7):572-6.

PMID:
17596796
19.

Rapid molecular discrimination between infection with wild-type varicella-zoster virus and varicella vaccine virus.

Lässker U, Harder TC, Hufnagel M, Suttorp M.

Infection. 2002 Oct;30(5):320-2.

PMID:
12382096
20.

Development of varicella vaccine.

Takahashi M, Asano Y, Kamiya H, Baba K, Ozaki T, Otsuka T, Yamanishi K.

J Infect Dis. 2008 Mar 1;197 Suppl 2:S41-4. doi: 10.1086/522132.

PMID:
18419406

Supplemental Content

Support Center